Meeting
2013 ASCO Annual Meeting
Targeted next-generation sequencing (NGS) of circulating tumor cells (CTCs) in hormone-sensitive prostate cancer (HSPC).
Authors
Stephen V. Liu
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA
Stephen V. Liu , Paul W. Dempsey , William Strauss , Yucheng Xu , Tong Xu , Jacek K. Pinski , Tanya B. Dorff , David I. Quinn , Timothy J. Triche , Jessamine Winer-Jones , Andre De Fusco , Janine McMurdie , Amir Goldkorn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Circulating Tumor Cells
Citation
J Clin Oncol 31, 2013 (suppl; abstr 11040)
DOI
10.1200/jco.2013.31.15_suppl.11040
Abstract #
11040
Poster Bd #
43C
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.
First Author: Razelle Kurzrock
Poster
2021 ASCO Annual Meeting
Complementary detection of genomic alterations in metastatic castration‑resistant prostate cancer (mCRPC) from CheckMate 9KD through analyses of tumor tissue and plasma DNA.
First Author: Mark Sausen
Poster
2018 Genitourinary Cancers Symposium
Biological significance of novel populations of prostate cancer circulating tumor cells (CTC).
First Author: Ian D. Davis
Poster
2016 ASCO Annual Meeting
Cell-free DNA sequencing-guided therapy in a prospective clinical trial: NEXT-2 trial—A feasibility analysis.
First Author: Jeeyun Lee